Today, Congressman Stephen F. Lynch (D-Boston) called on the House Oversight and Government Reform Committee to hold a hearing to examine Mylan’s pricing practices after the dramatic cost increase for the EpiPen. The EpiPen is used to administer epinephrine, which treats life-threatening allergic reactions. Mylan has a virtual monopoly on epinephrine auto-injectors and increased the retail price for a two-pack of the EpiPen from less than $100 in 2007 to more than $600 in 2016.
“Families in the 8th Congressional District have raised concerns about the cost to fill EpiPen prescriptions. Parents should not have to worry about whether they can afford epinephrine for their children. Seniors should not be limited in access to this lifesaving drug. These skyrocketing prescription drug prices are unacceptable and we need ensure there is thorough oversight of pharmaceutical companies,” said Congressman Lynch. “The Oversight Committee must promptly examine the burdensome cost increase of the EpiPen in addition to other issues affecting cost and access to prescription drugs.”
In particular, Congressman Lynch’s letter notes that while Mylan announced the introduction of a generic form and coupons to help patients cope with the increased cost, the company has not committed to lowering the price for the EpiPen. Without lowering the price, patients and taxpayers will continue to bear the exorbitant cost of the EpiPen, while Mylan continues to profit.
The text of the letter is available here.
- (304.9 KBs)